免疫療法薬の市場規模、シェア、成長分析、タイプ別、用途別、投与経路別、流通チャネル別、エンドユーザー別、地域別 - 産業予測、2024年～2031年

免疫療法薬の世界市場規模は、2022年に約2,474億4,000万米ドルと評価され、2023年の2,853億米ドルから上昇し、予測期間（2024年～2031年）のCAGRは15.3%で、2031年には7,728億7,000万米ドルに達すると予測されています。

免疫療法薬の世界市場は、慢性疾患、特に糖尿病の罹患率の上昇が主な要因となって大きな成長を遂げており、国際糖尿病連合によると、2021年には20～79歳の成人が5億3,700万人罹患し、2045年には7億8,300万人にまで拡大すると予測されています。市場の大手企業は、免疫療法の研究を強化するため、革新的な製品開発や戦略的提携にますます力を注いでいます。2021年1月に発表された、高リスクのCOVID-19患者の入院を予防するモノクローナル抗体の有効性を強調する知見に代表されるように、COVID-19の流行は免疫療法関連薬の需要を増大させ、この成長をさらに加速させています。免疫療法製品に対する規制当局の承認の急増も市場の拡大を支えています。主な成長要因としては、従来の治療法よりも標的治療法への嗜好の高まり、バイオシミラーのイントロダクション、生活習慣病の増加、モノクローナル抗体に対する消費者の需要の高まりなどが挙げられます。さらに、共同研究の急増、研究所の設立、バイオテクノロジー企業や製薬企業による多額の研究開発投資も市場の勢いに寄与しています。これらのダイナミクスが相俟って、免疫療法薬の開発・商業化には今後数年のうちに確固たる展望が開けるものと思われます。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 主な成功要因
• 競合の程度
• 主な投資機会
• 市場のエコシステム
• 顧客と購買基準の分析
• バリューチェーン分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 技術分析
• ケーススタディ分析
• 規制情勢

免疫療法薬市場：タイプ別

• 市場概要
• 抗体医薬品
• 阻害薬
• インターフェロンとインターロイキン
• がんワクチン
• その他タイプ

免疫療法薬市場：投与経路別

• 市場概要
• 静脈内投与経路
• 皮下投与経路
• その他の投与経路

免疫療法薬市場：用途別

• 市場概要
• がん
• 自己免疫疾患および炎症性疾患
• 血液
• 骨
• 神経
• その他の用途

免疫療法薬市場：流通チャネル別

• 市場概要
• 小売薬局
• オンライン薬局
• 病院薬局

免疫療法薬市場：エンドユーザー別

• 市場概要
• 病院・クリニック
• 外来手術センター
• その他

免疫療法薬市場：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • アラブ首長国連邦諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Merck & Co., Inc.（United States）
• Johnson & Johnson Services, Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• AstraZeneca（United Kingdom）
• Pfizer Inc.（United States）
• Amgen Inc.（United States）
• Novartis AG（Switzerland）
• Eli Lilly and Company（United States）
• Sanofi（France）
• Bristol-Myers Squibb Company（United States）
• Gilead Sciences, Inc.（United States）
• Takeda Pharmaceutical Company Limited（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• AbbVie Inc.（United States）
• GSK PLC（United Kingdom）
• Immunocore Holdings Plc（United Kingdom）
• Astellas Pharma Inc.（Japan）
• Genmab A/S（Denmark）
• MacroGenics, Inc.（United States）
• Ferring BV（Switzerland）

Global Immunotherapy Drugs Market size was valued at around USD 247.44 billion in 2022 and is expected to rise from USD 285.30 billion in 2023 to reach a value of USD 772.87 billion by 2031, at a CAGR of 15.3% over the forecast period (2024-2031).

The global market for immunotherapy drugs is witnessing significant growth, primarily driven by the rising incidence of chronic diseases, particularly diabetes, which affected an estimated 537 million adults aged 20-79 in 2021 and is projected to escalate to 783 million by 2045, according to the International Diabetes Federation. Major market players are increasingly focusing on innovative product development and strategic partnerships to enhance research in immunotherapy. The COVID-19 pandemic has further accelerated this growth by increasing the demand for immunotherapy-related drugs, exemplified by findings published in January 2021 that highlighted the effectiveness of monoclonal antibodies in preventing hospitalizations for high-risk COVID-19 patients. The surge in regulatory approvals for immunotherapy products also supports market expansion. Key growth factors include the growing preference for targeted therapies over conventional treatments, the introduction of biosimilars, the rise in lifestyle-related disorders, and heightened consumer demand for monoclonal antibodies. Additionally, an upsurge in collaborations, the establishment of research laboratories, and significant R&D investments by biotechnology and pharmaceutical firms contribute to the market's momentum. Together, these dynamics are poised to create a robust landscape for immunotherapy drug development and commercialization in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immunotherapy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immunotherapy Drugs Market Segmental Analysis

Global Immunotherapy Drugs Market is segmented by Type, Route of Administration, Application, Distribution Channel, End User and Region. Based on Type, the market is segmented into Antibody Drugs Inhibitor Drugs, Interferons and Interleukins, Cancer Vaccines, and Other Types. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Other Routes of Administration. Based on Application, the market is segmented into Cancer, Autoimmune and Inflammatory Diseases, Hematology, Osteology, Neurology, and Other Applications. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Immunotherapy Drugs Market

The global immunotherapy drugs market is significantly propelled by the rising prevalence of chronic diseases, notably cancer, autoimmune disorders, and infectious diseases. As lifestyles evolve and populations age, the demand for innovative and effective treatment options surges, creating a substantial market opportunity. Immunotherapy offers promising solutions, often leading to potential cures and improved patient outcomes, which further drives its adoption. Additionally, heightened awareness and advancements in diagnostic techniques contribute to early detection and treatment, thereby increasing the patient pool relying on immunotherapeutic agents. Collectively, these factors are expected to stimulate robust growth in the immunotherapy drugs market.

Restraints in the Global Immunotherapy Drugs Market

The Global Immunotherapy Drugs market faces significant restraints due to the challenging development process associated with these treatments. High costs linked to extensive clinical trials, research, and development pose a considerable barrier, limiting the entry of new players into the market. Additionally, the intrinsic complexity of immune system interactions necessitates personalized or group-oriented therapies, further complicating development and increasing expenses. These combined factors can deter investment and innovation, consequently hindering the emergence of new therapies and slowing overall market growth. The intricate regulatory landscape also contributes to these challenges, creating an environment that is less conducive to rapid advancement in immunotherapy.

Market Trends of the Global Immunotherapy Drugs Market

The Global Immunotherapy Drugs market is increasingly shifting towards personalized immunotherapy, fueled by advancements in precision medicine, genomics, and genetic engineering. This trend enables the development of treatments tailored to individual genetic profiles, disease history, and unique immune system characteristics, enhancing efficacy and minimizing side effects. With promising outcomes from clinical trials, pharmaceutical companies are investing significantly in personalized approaches, anticipating this shift will transform treatment paradigms for a range of conditions, including autoimmune diseases and cancers. As a result, the demand for bespoke immunotherapeutic solutions is set to accelerate, marking a pivotal evolution in the immunotherapy landscape.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Customer & Buying Criteria Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Pricing Analysis
• Patent Analysis
• Technology Analysis
• Case Study Analysis
• Regulatory Landscape

Immunotherapy Drugs Market, By Type

• Market Overview
• Antibody Drugs
• Inhibitor Drugs
• Interferons & Interleukins
• Cancer Vaccines
• Other Immunotherapy Drugs

Immunotherapy Drugs Market, By Route of Administration

• Market Overview
• Intravenous Route of Administration
• Subcutaneous Route of Administration
• Other Routes of Administration

Immunotherapy Drugs Market, By Application

• Market Overview
• Cancer
• Autoimmune & Inflammatory Diseases
• Hematology
• Osteology
• Neurology
• Other Applications

Immunotherapy Drugs Market, By Distribution Channel

• Market Overview
• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

Immunotherapy Drugs Market, By End User

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Immunotherapy Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunocore Holdings Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring BV (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments